Compare Kinross Gold Corporation (KGC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? Kinross Gold Corporation trades at $22.45 (market cap $27.68B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Kinross Gold Corporation is far larger — about 3.7× Spyre Therapeutics Inc. Common Stock's market cap, and Kinross Gold Corporation pays a 0.68% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinross Gold Corporation for 53 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KGC | SYRE | |
|---|---|---|
Market Cap | $27.68B | $7.52B |
Volume | 5,395,404 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $108.92 |
52-Week Low | $22.24 | $22.18 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $25.76B | $6.52B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $22.24, down 5.56% amid production guidance cuts and legal investigations, yet maintains strong fundamentals with robust earnings beats and a 37.52% net margin. Technical indicators show bearish momentum with support at $23, while fundamentals reveal impressive revenue growth from $3.5B in 2022 to $7.05B in 2025, supported by a low P/E of 8.91 and rising cash flow.
The stock presents a value opportunity with a consensus price target of $38.80 (74% upside), but faces near-term headwinds from operational setbacks and legal scrutiny. Long-term prospects remain solid due to gold price strength and shareholder returns, though investors must weigh production risks against valuation appeal.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
